Clean Gene Editing And Licensing With Cas-CLOVER
Our Cas-CLOVER gene editing technology helps eliminate off-target mutations and is available through a simple license.
Easily designed and deployed reagents
Fast, dCas-guided sequence recognition
2 gRNAs match target and subunit dimerizes before cleavage
Dimerization Of Cas-CLOVER Means More Precision And High Efficiency
Cas-CLOVER utilizes the dimerization of the Clo051 nuclease to cleave DNA. The dCas fused to Clo051 is mutated so it is unable to cut DNA, serving only as a guide to the target sequence. Since Cas-CLOVER must dimerize to cut, our system requires two guide RNAs (gRNAs) to target the gene of interest, making our system highly targeted and functional only when Cas-CLOVER dimerizes at the correct target site.
Our Cas-CLOVER system requires two gRNAs for gene targeting, resulting in minimal off-targets. In a recent publication from our sister company, Poseida Therapeutics, potential off-target sites were identified and Cas-CLOVER demonstrated a maximum potential off-target indel rate of under 1% (Madison et al 2022).
Due to Clo051’s nuclease activity, Cas-CLOVER results in large deletions, ranging from 8 to 50 base pairs (bp). Large deletions result in more disruption of gene expression and function and enable rapid screening via traditional DNA agarose gels.
Validated In Mammalian Cells, Yeast, and Plants
We specialize in multiple industries, allowing us to apply Cas-CLOVER and piggyBac technologies into broad real world applications.
Bioprocessing and cell line engineering to produce human or non-human therapeutics
Bioprocessing and strain improvement to produce therapeutics, industrial enzymes, compounds or biofuels
Enable plant modifications that may not require GMO labels and for the production of novel therapeutics
Optimizing Your Gene Editing Research?
Contact us to learn more about our innovative gene editing technology.